Aveeno and Mayo Clinic Form Three-Year Research Partnership to Advance Colloidal Oatmeal Science and Skin Health

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. Roots of a Partnership: Aveeno's "Oat Science" and Mayo Clinic's Dermatology Legacy
  4. What the Three-Year Program Will Cover: Preclinical, Clinical, and Educational Tracks
  5. Colloidal Oatmeal: Science, Mechanisms, and Gaps in Understanding
  6. Designing Clinical Trials for Sensitive and Compromised Skin: Key Considerations
  7. Translating Findings into Clinical Practice: Education, Guidelines, and Patient Communication
  8. Innovation Beyond the Ointment Jar: Formulation Science and Emerging Technologies
  9. Regulatory and Commercial Context: Claims, Monographs, and Ethical Considerations
  10. Addressing Criticisms and Limitations: Industry Partnerships, Bias Risk, and Scientific Rigor
  11. Measuring Impact: What Success Will Look Like
  12. How This Partnership Fits Into a Broader Research Ecosystem
  13. Practical Guidance for Clinicians and Patients Today
  14. Challenges Ahead: Implementation, Access, and Equity
  15. Looking Ahead: Timelines, Expectations, and Transparency
  16. FAQ

Key Highlights:

  • Aveeno and Mayo Clinic launched a three-year collaboration focused on preclinical and clinical research, professional education, and new strategies to deepen understanding of colloidal oatmeal and skin health.
  • The partnership builds on decades of clinical evidence and Mayo Clinic’s early reports on colloidal oatmeal, aiming to translate laboratory findings into improved treatments and educational resources for clinicians and patients.

Introduction

Aveeno, the long-standing consumer brand known for oat-based skincare, has formalized a three-year collaboration with Mayo Clinic intended to accelerate scientific research and professional education around skin health. The agreement ties a commercial leader in formulation and product distribution to an academic medical center with a historical record in dermatologic research. The collaboration targets both laboratory investigations and clinical trials, while also committing resources to clinician education and strategies that could broaden the reach of evidence-based skin care for people with sensitive or compromised skin.

The announcement marks a notable moment for an ingredient with roots in mid-20th century medicine: colloidal oatmeal. Mayo Clinic authors were among the first to document the therapeutic value of oat baths for skin conditions in the early 1950s. Since then, clinical trials — including randomized studies that compared colloidal-oatmeal formulations to vehicles — have demonstrated symptom relief for xerosis and pruritus. The new collaboration pairs that historical clinical baseline with modern tools: preclinical methods, patient-centered outcomes, and professional education programs designed to bridge research findings and everyday care.

Roots of a Partnership: Aveeno's "Oat Science" and Mayo Clinic's Dermatology Legacy

The partnership rests on two complementary strengths. Aveeno brings decades of product development, formulation science, and access to diverse consumer usage data. Mayo Clinic contributes multidisciplinary clinical expertise, a history of dermatologic research and patient care, and the institutional rigor of academic clinical investigation.

Colloidal oatmeal first appears in dermatology literature in the mid-20th century. Mayo Clinic physicians published early observations on the use of oatmeal baths for acute and chronic dermatoses, a clinical practice still employed in hospitals and outpatient care. Over time, research refined understanding of how finely milled or colloidally prepared oat extracts interact with the skin. A pivotal randomized controlled trial published in 2014 compared an “active” moisturizing lotion containing colloidal oatmeal to its vehicle and found superior relief for xerosis and pruritus — symptoms central to many dermatological conditions. That trial remains a touchstone for claims about efficacy.

Aveeno’s brand identity — centered on what it calls “oat science” — has been shaped by these clinical foundations. The company markets topical formulations that target sensitive and compromised skin, leaning on both internal research and the published literature. The new formal collaboration with Mayo Clinic signals a deepening of the research relationship, moving beyond product validation to address biological mechanisms, broader clinical contexts, and clinician education.

Real-world context: inpatient dermatologic care often uses oatmeal baths to soothe widespread eczema, drug eruptions, or toxic-irritant dermatitis cases. In outpatient practice, clinicians commonly recommend oatmeal-containing cleansers and emollients for older adults living with xerosis and for infants with mild atopic dermatitis. Institutional endorsement by a center such as Mayo Clinic would carry weight for clinicians seeking evidence-based guidance.

What the Three-Year Program Will Cover: Preclinical, Clinical, and Educational Tracks

The announced program spans three primary tracks:

  • Preclinical research to probe mechanisms and refine biomarkers that explain how colloidal oatmeal works on compromised skin.
  • Clinical trials designed to test efficacy and safety across populations with varying ages, skin types, and degrees of skin barrier dysfunction.
  • Professional education initiatives to inform practicing clinicians about new findings and practical approaches to managing sensitive skin.

Preclinical work will likely involve in vitro models of epidermal barrier function, ex vivo human skin experiments, and possibly animal models to explore inflammation, barrier repair, and molecular signaling pathways. Those experiments can reveal how oat-derived components interact with keratinocytes, immune cells, lipid synthesis pathways, and cutaneous microbiota.

Clinical investigations may range from short-term proof-of-concept trials to larger randomized, controlled studies with objective and patient-reported endpoints. Objective measures could include transepidermal water loss (TEWL), epidermal thickness, and inflammation markers collected from skin biopsies or noninvasive sampling. Patient-reported outcomes would capture pruritus intensity, sleep disturbance, quality of life, and symptom relief timelines.

Education and outreach are positioned as a core deliverable. That implies curriculum development for dermatologists, primary care clinicians, nursing staff, and perhaps patient-facing materials. The stated goal: to translate laboratory and clinical insights into practice changes that improve care for people with sensitive or compromised skin.

A practical example: an evidence-informed clinician education module on managing xerosis in older adults could combine guidance on appropriate emollient selection, bathing practices, and when to escalate to topical anti-inflammatory agents. If the collaboration yields clear comparative data showing faster barrier restoration with a specific oat-derived formulation or regimen, that evidence would underpin those educational messages.

Colloidal Oatmeal: Science, Mechanisms, and Gaps in Understanding

Colloidal oatmeal is not a single chemical entity. It represents a finely milled preparation of oat grain (Avena sativa) that contains a mixture of lipids, proteins, polysaccharides (notably beta-glucans), and phenolic compounds. Several mechanistic pathways have been proposed for its skin benefits:

  • Barrier support: Oat lipids and starches can form a physical emollient layer, reducing water loss and restoring skin pliability.
  • Anti-inflammatory effects: Avenanthramides, phenolic compounds found in oats, possess antioxidant and anti-inflammatory properties that may modulate cytokine release in the epidermis.
  • Soothing and anti-itch actions: Oat components may inhibit pathways implicated in pruritus signaling. Clinical reports indicate reductions in itch intensity after topical oat application.
  • Microbiome interactions: Prebiotic-like components could influence skin surface microbial communities, although this remains an emerging area of investigation.

Clinical research supports symptomatic improvement in xerosis and pruritus. The 2014 randomized controlled trial compared a colloidal-oatmeal-containing moisturizer to its inactive vehicle and found clinically meaningful reductions in dryness and itch. That trial strengthened claims that the active ingredient contributes beyond simple moisturizing properties.

Yet questions remain. What are the dose–response relationships? Which specific oat components drive measurable clinical benefits? How does colloidal oatmeal interact with widely used topical corticosteroids, calcineurin inhibitors, or barrier repair therapies? Which patient populations derive the greatest benefit — for example, infants with atopic dermatitis, chemotherapy patients with barrier disruption, or older adults with senile xerosis? The collaboration with Mayo Clinic sets up a platform to address these unknowns with robust, reproducible methods.

Real-world comparison: just as the active ingredient in a pharmaceutical needs quantification and mechanism for regulatory and clinical acceptance, botanical and complex mixtures such as colloidal oatmeal require equivalent rigor to move from tradition and marketing into standard guideline recommendations. Establishing specific, reproducible biomarkers will be essential for that transition.

Designing Clinical Trials for Sensitive and Compromised Skin: Key Considerations

Conducting trials in populations with sensitive or compromised skin raises particular challenges. Protocols must balance rigorous endpoints with patient comfort and ethics. Key design considerations include:

  • Selection of endpoints: Combine objective measures (TEWL, corneometry, inflammatory markers) with validated patient-reported outcomes (itch scales, Dermatology Life Quality Index). A multi-dimensional approach captures both physiological change and lived experience.
  • Comparator arms: Vehicle-controlled trials remain important to separate moisturizing effects from ingredient-specific benefits. Active comparators (e.g., ceramide-rich emollients) can establish relative effectiveness.
  • Duration and follow-up: Barrier repair can occur over days to weeks. Trials should include short-term steps for symptom relief and longer-term follow-up for durability, relapse, and safety.
  • Population diversity: Include participants across age groups, full range of skin tones, and comorbidities that influence barrier function (e.g., diabetes, chronic kidney disease). This improves generalizability and addresses historical gaps in dermatology research representation.
  • Concomitant therapies: Clear rules for permitted rescue medications (topical corticosteroids, antihistamines) must be predefined to avoid confounding results.
  • Safety and tolerability monitoring: Although colloidal oatmeal is generally well tolerated, monitoring for allergic contact dermatitis, irritation, or rare adverse events is necessary, especially when new formulations or higher concentrations are tested.

An example design: a three-arm, randomized trial in adults with moderate xerosis comparing (1) colloidal-oatmeal moisturizer, (2) ceramide-dominant emollient, and (3) vehicle, with primary endpoint TEWL reduction at two weeks and secondary endpoints itch scores and patient global impression of change. Stratification by baseline severity and skin tone would allow subgroup analysis.

Robust statistical planning must anticipate placebo effects that are notable in topical therapies. Trials should be adequately powered to detect clinically meaningful differences and to support regulatory or guideline claims.

Translating Findings into Clinical Practice: Education, Guidelines, and Patient Communication

Generating new data is only the first step. The partnership emphasizes professional education as a mechanism for translating discoveries into routine care.

Clinician education can take multiple forms:

  • Peer-reviewed publications presenting trial data with transparent methodology and conflict-of-interest disclosures.
  • Continuing medical education (CME) modules that summarize practical implications and stepwise treatment algorithms.
  • Grand rounds or specialty symposia hosted jointly by Mayo Clinic and professional societies.
  • Point-of-care decision aids for primary care clinicians and nurses who manage patients with common skin complaints.

Patient-facing education is equally important. Clear instructions on bathing habits, emollient application frequency, and safe use in infants or older adults reduce misuse and increase adherence. Simple, evidence-based messages improve outcomes more than unverified marketing claims.

A practical illustration: many older adults apply emollients only sporadically, often after showers when the skin is already dry. An education module that demonstrates immediate application to damp skin, evidence for frequency, and selection criteria for specific emollient types would likely increase effectiveness.

Professional endorsement matters. If Mayo Clinic authors publish high-quality trials demonstrating specific benefits for colloidal oatmeal formulations, professional societies and guideline panels may incorporate those findings into standard recommendations. That would shift colloidal oatmeal from routine advice to evidence-backed practice, influencing formularies, inpatient protocols, and insurer reimbursement decisions for certain therapeutic contexts.

Innovation Beyond the Ointment Jar: Formulation Science and Emerging Technologies

Formulation science will determine whether new evidence translates into measurable clinical advantages. Several avenues of innovation merit attention:

  • Targeted delivery systems: Encapsulation techniques (liposomes, solid lipid nanoparticles) could enhance penetration of active oat components into the stratum corneum without increasing irritation risk.
  • Combining actives: Formulations that pair colloidal oatmeal with ceramides, niacinamide, or low-potency anti-inflammatories might yield synergistic barrier repair and itch control.
  • Microbiome-friendly products: Preserving or promoting beneficial skin microbes while inhibiting pathogenic overgrowth could reduce flares in conditions such as atopic dermatitis.
  • Digital adherence tools: Mobile apps that remind patients to apply emollients and track symptoms can strengthen trial endpoints and real-world effectiveness.
  • Sustainable sourcing and manufacturing: As consumers and institutions prioritize environmental impact, traceability and sustainable oat sourcing may influence product adoption.

Each innovation introduces regulatory and safety questions. Delivery systems that alter skin penetration rates may change safety profiles and therefore require specific clinical data. Combining multiple active ingredients complicates attribution of effect. The collaboration’s preclinical track can test such strategies ahead of clinical translation.

Real-world analogy: in wound care, the evolution from simple dressings to bioactive dressings with growth factors and scaffolds required staged laboratory validation before broad clinical adoption. A similar staged approach will help oat-based innovations move from promising concepts to widely accepted therapies.

Regulatory and Commercial Context: Claims, Monographs, and Ethical Considerations

The commercial landscape shapes how research findings are translated into product labels and clinical recommendations. In the United States, colloidal oatmeal is recognized in the FDA’s over-the-counter (OTC) skin protectant monograph, which allows certain claims when products meet monograph specifications. That regulatory status facilitates marketing of colloidal-oatmeal-containing products for barrier protection and symptomatic relief. However, making therapeutic claims beyond the monograph — for example, disease-modifying statements for atopic dermatitis — requires robust clinical evidence and potentially different regulatory pathways.

Kenvue, the corporate owner of Aveeno, operates within a commercial framework that must reconcile marketing objectives with scientific integrity. Forward-looking statements are standard in corporate releases; they describe anticipated outcomes but are not guaranteed. Industry-funded research has produced many high-quality findings, but it also mandates transparent handling of conflicts of interest, data availability, and independent peer review.

Practical considerations:

  • Labeling: Demonstrating superiority versus vehicle supports stronger label claims about symptom relief.
  • Reimbursement: Demonstration of clinical benefit in specific patient populations (e.g., hospitalized patients with severe dermatitis) may allow institutional procurement or formulary placement.
  • International markets: Regulatory requirements differ worldwide; evidence packages may need tailoring to meet jurisdictional standards.

Ethical transparency is paramount. Well-designed contracts and publication agreements should ensure that Mayo Clinic investigators retain rights to analyze and publish data, that study methods are disclosed, and that raw data be available for independent verification where appropriate. Such practices build trust among clinicians and patients.

Addressing Criticisms and Limitations: Industry Partnerships, Bias Risk, and Scientific Rigor

Industry–academic collaborations attract scrutiny. Valid concerns include potential bias in study design, selective reporting, and marketing-driven interpretation of marginal results. These concerns are addressable through rigorous safeguards:

  • Pre-registration of trial protocols with detailed endpoints and statistical plans.
  • Independent data monitoring committees for larger trials.
  • Commitment to publish negative as well as positive findings.
  • Peer-reviewed publication and open-access where feasible to maximize dissemination.
  • Clear disclosure of funding sources and any competing interests.

Another limitation stems from the complexity of colloidal oatmeal as a multi-component mixture. Identifying active moieties requires careful fractionation studies and standardized characterization. Without standardization, batch-to-batch variability could affect reproducibility and clinical outcomes.

Finally, patient heterogeneity remains a scientific challenge. Skin phenotype, genetic predisposition, environmental exposures, and comorbid conditions interact with topical therapies. Trials must embrace this complexity through stratified analyses and recruitment strategies designed to reflect real-world populations.

Measuring Impact: What Success Will Look Like

Concrete metrics will determine whether the collaboration achieves its stated goals. Potential success indicators include:

  • Publication of peer-reviewed preclinical and clinical studies that elucidate mechanisms and demonstrate clinically meaningful outcomes.
  • Inclusion of colloidal-oatmeal-based recommendations in clinical guidelines for xerosis, pruritus management, or supportive care in specific conditions.
  • Measurable improvements in patient-reported outcomes and objective endpoints in clinical practice settings following education interventions.
  • New or refined formulations supported by evidence demonstrating superior or faster barrier repair, itch reduction, or tolerability.
  • Uptake of educational modules by clinicians, measured through CME credits, changes in prescribing or recommendation patterns, and patient care metrics.
  • Broader access to evidence-based products in hospital formularies and community settings, particularly in populations with limited resources.

These outcomes would reflect both scientific progress and public health benefit. For example, a measurable decline in eczema-related sleep disturbance and improvement in quality-of-life scores on a population level (as seen in a well-implemented program in primary care clinics) would be a meaningful public-health endpoint.

How This Partnership Fits Into a Broader Research Ecosystem

Industry–academic collaborations are common in dermatology and beyond. They combine resources for larger or more complex projects than either partner might pursue independently. Successful models balance the speed and scalability of industry with academic rigor and transparency. For clinicians and patients, such partnerships can accelerate translation of bench findings into bedside practice.

Examples from other therapeutic areas illustrate the potential: collaborative vaccine research accelerated timeline and innovation during public health emergencies; oncology partnerships enabled biomarker-driven trials that redefined standard-of-care treatments. In dermatology, partnering on common-sense topics — barrier repair, anti-itch therapies, antimicrobial stewardship — can yield practical gains that affect daily care.

This collaboration specifically targets an ingredient used across age groups and settings, from neonatal care to geriatric nursing homes. That breadth increases potential impact but also raises the need for careful, population-specific research.

Practical Guidance for Clinicians and Patients Today

While results from the new collaboration will unfold over years, clinicians can apply existing evidence pragmatically:

  • Recommend colloidal-oatmeal-containing emollients as part of a barrier-repair regimen for xerosis and mild pruritus when there are no contraindications.
  • Advise immediate application of emollients to damp skin after bathing to maximize hydration.
  • Use vehicle-controlled trial data to set realistic expectations: colloidal oatmeal can reduce dryness and itch for many patients, but response varies.
  • Reserve escalation to topical corticosteroids or other anti-inflammatory agents for inflammatory flares not controlled by emollients and symptom management.
  • In hospitalized patients with widespread dermatitis, oatmeal baths remain a reasonable adjunctive therapy, with attention to bathing logistics and skin tolerance.
  • For infants and sensitive skin, choose fragrance-free, preservative-minimized formulations and monitor for signs of irritation or allergy.

Clinicians should watch for new evidence emerging from the collaboration that may refine these recommendations or identify patient subgroups who benefit most.

Challenges Ahead: Implementation, Access, and Equity

Translational research frequently encounters barriers unrelated to scientific validity. Implementation in real-world settings requires attention to cost, supply-chain stability, and clinician behavior. Access equity is a central concern: high-cost or specialty formulations may be out of reach for patients in low-resource settings unless manufacturers and health systems plan for affordability.

Supply-chain and sustainability issues can influence adoption as well. Sourcing oat ingredients responsibly and maintaining consistent quality at scale are operational tasks that affect product consistency and environmental footprint.

Finally, communication must be culturally competent and tailored. Skin care advice that ignores cultural practices or economic realities risks low adherence. Educational materials produced through the collaboration should be multilingual and consider diverse caregiving contexts.

Looking Ahead: Timelines, Expectations, and Transparency

The three-year timeframe sets a clear horizon but also constrains the scope of what can be achieved. Preclinical studies and small clinical trials can yield mechanistic insights and early efficacy signals within that period. Larger, multicenter randomized controlled trials and guideline integration will likely extend beyond three years.

Transparency around timelines, data sharing, and publication commitments will shape how the research community and public perceive the partnership. Independent validation of findings by external investigators will strengthen confidence and facilitate adoption.

The collaboration may also stimulate subsequent research, including investigator-initiated studies and comparative effectiveness research that tests oat-based formulations against other evidence-based emollients in diverse practice settings.

FAQ

Q: What exactly is "Triple Oat" and how does it differ from generic colloidal oatmeal? A: "Triple Oat" is a branded designation used by Aveeno to describe a specific formulation or combination of oat-derived ingredients intended to provide barrier repair and symptomatic relief. Branded formulations can differ from generic colloidal oatmeal in concentration, particle size, processing methods, and additional excipients. These differences can influence skin interaction and clinical outcomes, which is why controlled trials comparing branded formulations to vehicle and to other emollients are important.

Q: Will this collaboration lead to new Aveeno products? A: The collaboration focuses on research, education, and innovation. While new product development is possible, the announced goals emphasize generating scientific knowledge and translating evidence into practice. Any new product launches would depend on the outcomes of preclinical and clinical research, regulatory considerations, and business decisions.

Q: Is colloidal oatmeal suitable for infants and people with very sensitive skin? A: Existing clinical evidence indicates colloidal oatmeal-based formulations can be well tolerated across age groups, including infants and those with sensitive skin, provided formulations are free from common irritants such as fragrances or unnecessary preservatives. Clinicians should advise patch testing in cases with severe atopic dermatitis or suspected contact allergy and recommend formulations labeled for infant use.

Q: How does the collaboration manage potential conflicts of interest? A: The collaboration involves a commercial partner and an academic institution. Best practices include pre-registering trials, ensuring academic investigators retain the right to publish results irrespective of outcome, disclosing all funding sources and potential conflicts of interest, and subjecting studies to independent peer review. Readers should look for such disclosures in forthcoming publications.

Q: How long before clinicians might see guideline changes based on this work? A: Some initial findings — particularly preclinical data and small clinical trials — could be published within the three-year period. Guideline updates typically require a body of high-quality evidence and consensus; substantial guideline changes may therefore take longer than the initial collaboration window. However, strong, well-designed clinical trials demonstrating clear benefit could prompt earlier adoption in clinical practice.

Q: Are there safety concerns with using colloidal oatmeal? A: Colloidal oatmeal is generally well tolerated. Allergic contact dermatitis to oats is uncommon but possible. Safety monitoring in clinical trials will continue to evaluate tolerability, particularly for novel formulations or delivery systems that alter skin penetration. Patients with known oat or cereal allergies should consult clinicians before use.

Q: How will this research affect access in hospital and institutional settings? A: If studies demonstrate clear benefits for inpatient populations (e.g., reduced pruritus or faster barrier repair), institutions may consider including evidence-backed formulations on formularies. Cost-effectiveness analyses and procurement planning will influence uptake. The collaboration’s educational component may facilitate implementation if findings are robust.

Q: Will this work address diversity in clinical research, such as inclusion of darker skin tones? A: The announcement highlights a commitment to advancing skin wellness across ages and skin types. High-quality dermatologic research requires deliberate recruitment strategies to include diverse skin tones, ages, and comorbidities. Expectation for publications includes stratified analyses by relevant demographic and clinical variables.

Q: How can patients and clinicians stay updated on results from this collaboration? A: Monitor peer-reviewed journals for published trials and review announcements from Mayo Clinic and Aveeno/Kenvue. Professional society conferences and CME offerings will likely highlight significant findings, and reputable clinical news sources will summarize major developments.

Q: How does this partnership compare to other industry–academic collaborations? A: Collaborative models vary widely. Strong partnerships combine industry resources and access to real-world data with academic independence and methodological rigor. Comparatively, this collaboration follows a familiar template: clear objectives in research and education, a defined timeline, and a focus on translating evidence into practice. The ultimate measure of success will be the quality, transparency, and clinical relevance of the work produced.

This collaboration between a commercial skincare leader and a major academic medical center aims to deepen the scientific foundation for a widely used ingredient and to translate that evidence into better clinical care. The next phases of preclinical and clinical research, paired with clinician education initiatives, will determine whether colloidal-oatmeal-based strategies move from accepted practice to evidence-backed standard interventions for sensitive and compromised skin.